NCT00283621View on ClinicalTrials.gov

Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide

NACompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

June 2, 2003

Primary Completion Date

April 12, 2006

Study Completion Date

April 12, 2006

Conditions
Sarcoma
Interventions
DRUG

Aranesp (darbepoetin alfa)

DRUG

Neulasta (pegfilgrastim)

DRUG

Adriamycin

DRUG

Ifosfamide

Trial Locations (1)

77030

UT MDAnderson Cancer Center, Houston

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER